Metabolic Profiling in Schizophrenia
Author Information
Author(s): Rima Kaddurah-Daouk
Primary Institution: Duke University Medical Center
Hypothesis
Can metabolic profiling identify biomarkers for schizophrenia and assess the impact of early intervention on disease progression?
Conclusion
The study found that early treatment with antipsychotics can normalize abnormal metabolic profiles in some patients with schizophrenia.
Supporting Evidence
- Patients with schizophrenia showed an abnormal cerebrospinal fluid composition.
- Half of the patients returned to normal metabolic profiles with antipsychotic therapy.
- The study highlights the potential of metabolomics in understanding human disease.
Takeaway
Doctors can look at the chemicals in the fluid around the brain to see if people with schizophrenia are getting better when they take medicine.
Methodology
The study used nuclear magnetic resonance-based metabolic profiling to analyze cerebrospinal fluid in patients with schizophrenia.
Potential Biases
Possible confounding effects from other medications and disease states were not fully addressed.
Limitations
The study had a small sample size and used only one metabolomics platform, which may not capture the entire metabolome.
Participant Demographics
Patients included those with first onset, drug-naïve schizophrenia and brief psychotic disorder.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website